Pertuzumab (Perjecta) for HER2-positive metastatic breast cancer

Med Lett Drugs Ther. 2012 Jul 23;54(1395):59-60.
No abstract available

MeSH terms

  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • Docetaxel
  • Drug Approval
  • Female
  • Humans
  • Neoplasm Metastasis
  • Receptor, ErbB-2 / antagonists & inhibitors*
  • Taxoids / administration & dosage
  • Trastuzumab
  • United States
  • United States Food and Drug Administration

Substances

  • Antibodies, Monoclonal, Humanized
  • Taxoids
  • Docetaxel
  • Receptor, ErbB-2
  • pertuzumab
  • Trastuzumab